ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients

M. Z. Molnar, O. Cseprekal, M. Yazawa, M. Talwar, V. Balaraman, V. Mas, D. Maluf, R. Helmick, L. Campos, N. Nezakatgoo, C. Eymard, P. Horton, R. Verma, A. Jenkins, C. R. Handley, H. Snyder, C. Cummings, U. A. Agbim, B. Maliakkal, S. K. Satapathy, S. P. Nair, J. D. Eason

Methodist University Hospital Transplant Institute, Memphis, TN

Meeting: 2019 American Transplant Congress

Abstract number: 19

Keywords: Donors, unrelated, Hepatitis C, Kidney transplantation, Outcome

Session Information

Session Name: Concurrent Session: Kidney Donor Selection / Management Issues I

Session Type: Concurrent Session

Date: Sunday, June 2, 2019

Session Time: 2:30pm-4:00pm

 Presentation Time: 2:30pm-2:42pm

Location: Ballroom C

*Purpose: There are no data on the safety of kidney transplantation from hepatitis C (HCV) NAT positive donors to HCV naïve recipients. We report the preliminary data of 58 HCV negative recipients who received HCV NAT positive kidneys between March and October, 2018 in our center.

*Methods: All recipients received induction with Thymoglobulin 4.5 mg/kg and maintenance immunosuppression with tacrolimus, mycophenolic-acid and prednisolone. Treatment with a pan genotypic DAA regimen was offered to recipients at 1-3 months after complete recovery from the renal transplant and once HCV RNA was detected.

*Results: Tables 1 and 2 detail recipient and donor characteristics.

Recipient Characteristics
Age, years (mean (SD)) 52 (11)
Female (N (%)) 21 (36)
Caucasians (N (%)) 10 (17)
Time on dialysis, months (mean (SD)) 51 (30-75)
Diabetes (N (%)) 29 (50)
Peripheral vascular disease (N (%)) 7 (12)
Coronary artery disease (N (%)) 9 (16)
Medicare insured (N (%)) 46 (79)
Donor Characteristics
Age, years (mean (SD)) 32 (5)
Female (N (%)) 22 (38)
DCD (N (%)) 6 (10)
Diabetes (N (%)) 1 (2)
Hypertension (N (%)) 4 (7)
Caucasians (N (%)) 55 (95)
KDPI (mean (SD)) 51 (15)
KDPI without HCV component (mean (SD)) 24 (15)

The median (IQR) time between transplant and treatment initiation was 77 (68-90) days. The time waiting for insurance approval was 17 (12-25) days. All 58 patients became viremic (genotype: 1a (N=38), 1b (N=1), 2 (N=3) and 3 (N=16)). This Figure shows ALT levels and virus copies before and after treatment.

 border=

At this time 53 recipients were started on treatment. Forty out of 41 became PCR negative at 4 weeks of treatment. Fourteen patients completed treatment and were negative at the end of treatment. Four recipients had delayed graft function and one developed cellular rejection. The estimated GFR at 4, 12, and 16 weeks was 56±16 ml/min, 58±17 ml/min, and 66±16 ml/min, respectively.

*Conclusions: Kidney transplantation from Hepatitis C positive donors to negative recipients is safe and effective, but further long-term data is needed from this and other cohorts outside clinical trials. Using HCV positive kidneys in naïve recipients provides life-saving benefit with negligible risk.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Molnar MZ, Cseprekal O, Yazawa M, Talwar M, Balaraman V, Mas V, Maluf D, Helmick R, Campos L, Nezakatgoo N, Eymard C, Horton P, Verma R, Jenkins A, Handley CR, Snyder H, Cummings C, Agbim UA, Maliakkal B, Satapathy SK, Nair SP, Eason JD. Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/transplantation-of-kidneys-from-hepatitis-c-infected-donors-to-hepatitis-c-negative-recipients/. Accessed May 18, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences